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Abstract
Introduction The endogenous pain-relieving system depends in
part on the regulation of nociceptive signals through binding of
opioids to the corresponding opioid receptor. Interfering with
the trans-repression effect of downstream regulatory element
antagonist modulator (DREAM) on the transcription of the
opioid dynorphin-encoding prodynorphin (pdyn) gene might
enhance pain relief in the periphery.
Methods Expression levels were measured in osteoarthritis
(OA) synovial fibroblast-like cells (SFLCs) (n = 8) and in
peripheral blood mononuclear cells (PBMCs) from OA patients
(n = 53) and healthy controls (n = 26) by real-time polymerase
chain reaction. Lysed OA SFLCs were analyzed by
immunoprecipitation. Translation of DREAM mRNA was
inhibited by small interfering RNAs (siRNAs). Expressions of
DREAM, pdyn, and c-fos mRNAs were measured at 24, 48, and
72 hours after transfection.
Results The expression of DREAM mRNA was shown in both
healthy and OA SFLCs as well as PBMCs. Inhibiting
transcription using siRNAs led to a marked reduction in DREAM
expression after 24, 48, and 72 hours. However, no significant
changes in c-fos and pdyn expression occurred. In addition,
DREAM mRNA expression was significantly reduced in OA
patients with chronic pain (pain intensity as measured by a visual
analog scale scale of greater than 40), but no pdyn expression
was detectable.
Conclusion To our knowledge, this is the first report showing
the expression of DREAM in SFLCs and PBMCs on the mRNA
level. However, DREAM protein was not detectable. Since
repression of pdyn transcription persists after inhibiting DREAM
translation, DREAM appears to play no functional role in the
kappa opioid receptor system in OA SFLCs. Therefore, our data
suggest that DREAM appears not to qualify as a target in
peripheral pain management.
Introduction
The majority of the population is eventually confronted with
severe pain during their life. The acute painful stimulus signals
harm and therefore exerts a protective effect on the organism.
Frequent and repetitive stimulation leads to changes on the
molecular level and manifests the condition of chronic pain.
Chronic pain is a devastating and widespread problem, strik-
ing one in five adults across Europe [1]. The 'Pain in Europe'
study claims that more than 40% of patients suffering from
chronic pain experience their pain to restrict everyday activities
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and to worsen the quality of life [1]. Despite ongoing intensive
efforts, the control of chronic pain has not yet been achieved
[2]. Arthritic diseases cause enormous burdens in terms of
pain, crippling, and disability [3]. Recently, it has been demon-
strated that the use of small interfering RNAs (siRNAs) to the
pain-related cation channel P2X3 can be effective in the inhi-
bition of the neuropathic pain response in an animal model [4].
A potential target to modify nociception through siRNA ther-
apy is downstream regulatory element antagonist modulator
(DREAM) [5-7]. Carrion and colleagues [8,9] showed the
binding of DREAM to DNA, which implied a role in the hierar-
chical machinery regulating the rat dynorphin-encoding pro-
dynorphin  (pdyn)  gene in a Ca2+-dependent manner.
Dynorphin interacts preferably with the kappa opioid receptor
(KOR), which is part of the endogenous pain-relieving machin-
ery [10]. Thus, a diminution of the nociceptive signal is
achieved and less pain is perceived [10]. Cheng and col-
leagues [11] demonstrated the effects of the loss of DREAM
transcriptional repression in vivo. Higher basal levels of pdyn
mRNA expression were noted in the lumbar spinal cord in
dream-/- mice, which showed less sensitivity in all pain para-
digms tested [11]. The DNA-binding properties of DREAM
have also been shown to play a role in the regulation of genes
in the thyroid gland [12,13] and in hematopoetic progenitor
cells [14,15]. They have also been described to regulate mela-
tonin production in the pineal gland and the retina [16]. The
genes c-fos [9] and SLC8A3 (human Na+/Ca2+ exchanger
isoform 3) [17] are regulated in part by DREAM. The repres-
sion of transcription by DREAM bound to DNA is regulated not
only by changes in intracellular concentrations of Ca2+ but also
through the interaction with nuclear effector proteins in cAMP
signaling [18,19]. In addition, the multifunctional protein
DREAM was found to interact with potassium channels [20]
and presenilin, a protein thought to play a major role in Alzhe-
imer disease [21,22]. This interaction was also demonstrated
in vivo [23].
The following questions arise: (a) Does DREAM play a role in
the regulation of pdyn expression in chronic pain patients? (b)
Does targeted inhibition of DREAM expression in synovial
fibroblast-like cells (SFLCs) enhance the endogenous level of
dynophin action on KOR in the periphery?
Here, we present a study on the expression of DREAM mRNA
in osteoarthritis (OA) patients and the attempt to inhibit the
potential signaling of DREAM in SFLCs using siRNA. The tar-
geted inhibition of the expression of DREAM in SFLCs might
enhance the endogenous level of dynorphin acting on KOR,
using siRNAs locally in the periphery. If DREAM is a suitable
target in pain management, it might well be the switch to
reduce chronic pain in patients suffering from OA.
Materials and methods
Patients and tissue preparation
Synovial tissues were obtained from patients with knee OA (n
= 5 females, ages 37 to 57 years, visual analog scale [VAS]
score of 0 to 66, and n = 3 males, ages 27 to 38 years, VAS
score of 3 to 67) who underwent synovectomy during joint
replacement surgery. Synovial tissue from a healthy subject
with injuries, but without arthritis, was included as a control
(Department of Orthopedic Surgery, Schulthess Clinic,
Zurich, Switzerland). Blood was drawn from OA patients (n =
53) and healthy controls (n = 26; RehaClinic, Zurzach, Swit-
zerland). The procedure was approved by the local ethical
committees and all patients gave written informed consent. All
OA patients fulfilled the criteria of the American College of
Rheumatology for the classification of OA [24].
Isolation and culture of synovial fibroblast-like cells
The synovial tissue was minced and digested with dispase at
37°C for 60 minutes. After washing, cells were grown in Dul-
becco's modified Eagle's medium (Gibco, now part of Invitro-
gen Corporation, Carlsbad, CA, USA) supplemented with
10% fetal calf serum, 50 IU/mL penicillin-streptomycin, 2 mM
L-glutamine, 10 mM Hepes, and 0.5 μg/mL amphotericin B (all
from Invitrogen Corporation). Cell cultures were maintained in
a 5% CO2-humidified incubator at 37°C. Cultured SFLCs
were used between passages 4 and 9 for all experiments
described.
Isolation of peripheral blood mononuclear cells
Peripheral blood mononuclear cells (PBMCs) from whole
blood were isolated by gradient centrifugation using Ficoll
Paque™ Plus (Amersham Biosciences, now part of GE Health-
care, Little Chalfont, Buckinghamshire, UK). Blood was diluted
1:2 with phosphate-buffered saline (PBS), layered on top of
the corresponding amount of Ficoll Paque, and centrifuged at
450 g for 30 minutes at room temperature (with brakes off).
The cloudy interface representing the PBMCs was transferred
and washed three times in PBS, and centrifugation steps were
performed at 350 g at room temperature for 15 minutes and
twice for 10 minutes. Cells were subjected to RNA isolation.
RNA preparation and reverse transcription-polymerase 
chain reaction
Total RNA was isolated with the RNeasy Mini Kit (Qiagen,
Basel, Switzerland), including treatment with RNase-free
DNase I (Qiagen). To generate cDNA, total RNA was reverse-
transcribed in 20 μL of 1× reverse transcription-polymerase
chain reaction (RT-PCR) buffer containing 5.5 mM MgCl2,
500 μM of each dNTP, 2.5 μM random hexamers, 0.4 U/μL
RNase inhibitor, and 1.25 U/μL MultiScribe Reverse Tran-
scriptase (Applied Biosystems, Rotkreuz, Switzerland) at
48°C for 50 minutes. Total RNAs from normal human cerebel-
lum and spinal cord (both BD Biosciences, Clontech, Basel,
Switzerland) were used as positive controls. Non-reverse-tran-
scribed samples were used as negative controls in subse-Available online http://arthritis-research.com/content/10/3/R60
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quent real-time PCR experiments. The MMVL (Moloney murine
leukemia virus) reverse transcriptase (Invitrogen AG, Basel,
Switzerland) and corresponding agents were used for RT of
poly A+ mRNA according to standard protocols [25].
Polymerase chain reaction and cloning of DREAM 
amplicon
DREAM was amplified from 2 μL of generated cDNA, using
specific oligonucleotides (Microsynth, Balgach, Switzerland)
(Table 1) under the following conditions: 35 cycles with an ini-
tial denaturation of 5 minutes at 95°C, 30 seconds at 95°C, 30
seconds at 53°C, and 1 minute at 72°C, with a final extension
for 2 minutes at 72°C. For reamplification, 5 μL of the PCR mix
was subjected to the same PCR protocol using either nested
primers (Microsynth) (Table 1) or the same primer set in a
lower final concentration. The amplicon was purified using the
QIAexII Gel extraction kit (Qiagen), cloned using the TOPO TA
cloning® kit (Invitrogen AG), and sequenced (Synergene Bio-
tech GmbH, Schlieren, Switzerland).
Real-time polymerase chain reaction
Quantification of specific mRNA was performed by single-
reporter real-time PCR using the ABI Prism 7700 Sequence
Detection system (Applied Biosystems). Pre-designed gene-
specific primer pairs and probes for quantification of DREAM
(Hs00173310_m1) and pdyn (Hs00225770_m1) mRNA lev-
els were used (TaqMan® Gene Expression Assays; Applied
Biosystems). The level of c-fos mRNA was detected using
primers directed against c-fos (Microsynth) (Table 1) in an
SYBR green assay. 18S rRNA and GAPDH (glyceraldehyde-
3-phosphate dehydrogenase) were used as endogenous con-
trols. Relative gene expression was calculated using the com-
parative threshold cycle (Ct) method according to Livak and
Schmittgen [26].
Small interfering RNA generation and transfection
Different siRNAs were designed and generated according to
Donzé and Picard [27]. In brief, oligonucleotides and T7
primer (listed in Table 1) were combined in 50 μL of TE (Tris
ethylenediaminetetraacetic acid or Tris EDTA) (Ambion
[Europe] Ltd., now part of Applied Biosystems) and annealed
by heating the samples in a heating block for 2 minutes at
95°C and allowed to cool down for 6 hours in the block. The
double-stranded DNA hybrid served as a template for in vitro
transcription using T7 RNA polymerase (Stratagene Europe,
Amsterdam, The Netherlands) and was incubated at 37°C for
2 hours with corresponding buffers and 2 μL of 10 mM ATP,
GTP, CTP, and UTP (all from Invitrogen AG) in a total volume
of 50 μL. The remaining DNA was digested with RNase-free
DNase I (Roche Diagnostics, Mannheim, Germany). Sense
and antisense RNAs were mixed and allowed to anneal after
denaturation at 37°C for at least 1 hour. The T7 RNA polymer-
Table 1
Sequences of oligonucleotides used in polymerase chain reaction (PCR) and real-time PCR as well as for the generation of small 
interfering RNAs
Primers for conventional DREAM PCR
Forward Reverse
DREAM 5'-CCGGCTAAGGAAGTGACAAA-3' 5'-CAAAGGCGTTGAAGAGGAAG-3'
nDREAM 5'-GAAGGAGGGTATCAAGTG-3' 5'-TAAATGAGTTTGAAGGTGTC-3'
Primers for SYBR green assay real-time PCR
Forward Reverse
c-fos 5'-TAAATGAGTTTGAAGGTGTC-3' 5'-ACAGGAACCCTCTAGGGAAGA-3'
Oligonucleotides for the synthesis of siRNAs
Sense Antisense
siRNA1 5'-AAGGACAGGATCCACTTGACCTATAGTGAGTCGTATTA-3' 5'AAGGTCAAGTGGATCCTGTCCTATAGTGAGTCGTATTA3'
siRNA2 5'-AAGGTGAACTTGGTCTGGGCCTATAGTGAGTCGTATTA3' 5'-AAGGCCCAGACCAAGTTCACCTATAGTGAGTCGTATTA-3'
siRNA3 5'-AAGTAGAGATTAAAGGCCCACTATAGTGAGTCGTATTA-3' 5'-AAGTGGGCCTTTAATCTCTACTATAGTGAGTCGTATTA-3'
siRNA4 5'-AAGCTCATGATGTTCTCATCCTATAGTGAGTCGTATTA-3' 5'-AAGGATGAGAACATCATGAGCTATAGTGAGTCGTATTA-3'
siRNA5 5'-AAGTGTAGCAATCTGTTCACTATAGTGAGTCGTATTA-3' 5'-AAGTGAACAGATTGCTACACTATAGTGAGTCGTATTA-3'
siRNA-GFP 5'-ATGAACTTCAGGGTCAGCTTGCTATAGTGAGTCGTATTA-3' 5'-CGGCAAGCTGACCCTGAAGTTCTATAGTGAGTCGTATTA-3'
T7 5'-TAATACGACTCACTATAG-3'
siRNA3 (binding in the coding region of exon 6) and siRNA4 (spanning the non-coding exons 8 and 9) were used to interfere with endogenous 
DREAM mRNA and to analyze downstream target genes of DREAM gene regulation like pdyn and c-fos. Two different primers for DREAM are 
given. DREAM, downstream regulatory element antagonist modulator; GFP, green fluorescence protein; siRNA, small interfering RNA.Arthritis Research & Therapy    Vol 10 No 3    Reisch et al.
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ase synthesized small interfering double-stranded RNA (T7
siRNA) was precipitated and resuspended in 50 μL of TE
buffer.
The following kits were applied for efficient transfection of
SFLCs with double-stranded siRNAs: Gene Silencer™ siRNA
Transfection Reagent (Gene Therapy Systems, Inc., now part
of Genlantis, San Diego, CA, USA); instructions of the manu-
facturer were followed and applied to 24-well and 6-well for-
mats. The Human Dermal Fibroblast Nucleofactor™ Kit (amaxa
GmbH, Cologne, Germany) was used to transfect SFLCs with
1.5 μg of siRNA in a 6-well format. As described by Donzé and
Picard [27] and Caplen and colleagues [28], siRNA-green flu-
orescence protein (GFP) served as a negative control.
Immunoprecipitation and Western blot
SFLCs were washed with cold PBS and lysed with 50 mM
Tris-HCl, pH 7.6; 1% NP-40; 150 mM NaCl; 1 mM EDTA; 1
mM phenylmethanysulphonyl-fluoride; 1 μg/mL each aprotinin,
leupeptin, and pepstatin; and 1 mM Na3VO4 and incubated at
4°C for 10 minutes. Human brain tissue derived from the
occipital cortex area, which was obtained from autopsy less
than 4 hours after death (Institute of Neuropathology, Univer-
sity Hospital, Zurich, Switzerland; approved by the local ethical
committee) and stored at -80°C, served as a positive control
and was treated equally. For immunoprecipitation, the super-
natant, obtained after centrifugation, was mixed with 1 μg of
isotype matching control antibody mouse IgGs and Protein A/
G plus agarose (Santa Cruz Biotechnology, Inc., Santa Cruz,
CA, USA). The pre-cleared lysate was incubated overnight
with anti-DREAM antibody clone 40A5 (Upstate, Lake Placid,
NY, USA) (1:3,000) and Protein A/G agarose beads at 4°C.
Immunoprecipitates were collected by centrifugation. Beads
then were washed with ice-cold PBS, resuspended in 2 × Lae-
mmli buffer [25], and loaded on a reducing 12.5% polyacryla-
mid gel. Following SDS-PAGE, the gels were blotted on
Protran®  nitrocellulose transfer membrane (Schleicher &
Schüll GmbH, Dassel, Germany), blocked, and incubated with
anti-DREAM antibodies overnight. The ECL™ Western blot-
ting detection reagents (GE Healthcare) were used after incu-
bation with secondary goat anti-mouse horseradish
peroxidase antibody (Jackson ImmunoResearch Laboratories
Europe Ltd, Suffolk, UK). DREAM human recombinant protein
(Abnova, Taipei, Taiwan) was used as a control.
Statistical analysis
All data are expressed as mean ± standard error of the mean.
Comparisons of two groups were made using the Mann-Whit-
ney U test for unpaired data and the Wilcoxon test for paired
data. For comparison of three different patient groups, data
were analyzed by one-way analysis of variance (ANOVA) fol-
lowed by Tukey's honest significant difference. The Shapiro-
Wilk test was used to assess the distribution of the data. The
level of significance was set at a P value of less than 0.05. All
statistics were calculated using SPSS for Windows, version
11.5 (SPSS Inc., Chicago, IL, USA).
Results
Detection of DREAM mRNA in synovial fibroblast-like 
cells and peripheral blood mononuclear cells
Qualitative RT-PCR with nervous system-derived RNA
resulted in the amplification of a DREAM-specific transcript
and served as a positive control (Figure 1a). Initial amplification
of the SFLC-derived mRNA did not yield a detectable product.
Reamplification, using the same settings, resulted in an ampli-
con that matched the positive control in size (409 base pairs
[bp]) (Figure 1b). Subsequent nested PCR (amplicon size 276
bp) verified the presence of a DREAM-specific transcript in
OA SFLCs and normal SFLCs (NSFLCs) (Figures 1c and 1d).
All amplicons were cloned and their sequences were verified.
Quantitative expression of DREAM mRNA in OA SFLCs (13.9
± 0.6; n = 8) was measured using real-time PCR. Expression
levels in neuronal tissue (13.6 ± 0.76; n = 3) and NSFLCs
(13.9 ± 1.53; n = 1) served as controls. The expression of
DREAM mRNA was lower in PBMCs (16.46 ± 0.16; n = 19)
and synovial fluid cells, which both represent a heterogeneous
pool of different cell subpopulations (data not shown).
DREAM mRNA expression is reduced in osteoarthritis 
patients with high visual analog scale score
DREAM mRNA expression was analyzed in PBMCs from both
OA patients and healthy controls. The expression of DREAM
mRNA was detectable in 23/26 control subjects and in 23/53
OA patients. DREAM mRNA was significantly reduced by
63% in PBMCs from OA patients, with a pain score on the
VAS (0 to 100) of greater than 40 (n = 14) compared with
healthy controls. OA patients with a pain intensity of less than
or equal to 40 on the VAS (n = 9) displayed no significant
reduction in the expression of DREAM mRNA compared with
the healthy control group (ANOVA: F  (2,43) = 7.91; P  <
0.001) (Figure 2). However, mRNA expression of pdyn was
detectable neither in PBMCs derived from the healthy control
group nor in PBMCs from OA patients.
Inhibiting DREAM expression using small interfering 
RNAs
DREAM has been implicated to play a major role in pain trans-
mission by regulating the transcription of pdyn in the spinal
cord. DREAM-/- mice showed less pain sensitivity in all para-
digms tested [11]. To inhibit the blocking function of the
DREAM protein on pdyn gene expression in SFLCs, five T7
siRNAs were designed and tested (Figure 3a). The level of
DREAM expression in siRNA-GFP-transfected cells (relative
expression 13.78 ± 0.67) served as baseline control and was
not statistically different from mock-transfected cells (relative
expression 13.65 ± 0.21; mock/siRNA-GFP P = 0.686) (Fig-
ure 2). DREAM mRNA was repressed to 25% ± 4% of base-
line DREAM expression by siRNA1, 7.6% ± 1.8% by siRNA2,
13% ± 1.3% by siRNA3, 9% ± 0.8% by siRNA4, and 18.8%Available online http://arthritis-research.com/content/10/3/R60
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± 3.1% by siRNA5. Although detectable DREAM transcripts
were reduced to 14.17% ± 1.37% at 24 hours after transfec-
tion using siRNA3 and siRNA4 and remained at significantly
low levels for an additional 24 hours (16.23% ± 1.92%), no
significant changes in pdyn  and  c-fos  expression were
detected (data not shown). The level of DREAM mRNA
expression was still reduced to 40.76% ± 6.74% of baseline
expression at 72 hours after transfection (Figure 3b).
Detection of DREAM protein in synovial fibroblast-like 
cells
The monoclonal mouse anti-human DREAM antibody clone
40A5 precipitated DREAM protein from human brain tissue,
whereas no positive signal for DREAM protein could be
detected in OA SFLCs and PBMCs (Figure 4).
Discussion
DREAM, also known as calsenilin and KChIP3, is a member of
the recoverin/neuronal calcium sensor family of nuclear cal-
cium-binding proteins and so far has mainly been known to be
expressed in the nervous system [29-31]. To our knowledge,
this is the first report that demonstrates the presence of
DREAM transcripts in OA SFLCs (Figure 1) as well as PBMCs
and synovial fluid cells. DREAM was detected on the mRNA
level on both a qualitative and a quantitative basis. In vitro
DREAM transcription could be reduced significantly for more
than 48 hours in SFLCs using siRNAs (Figure 3). However,
the two target genes of DREAM transcriptional repression,
pdyn and c-fos, displayed no increase in gene transcription.
The basal transcription level of pdyn is very low in SFLCs. The
expression levels of neither pdyn nor c-fos displayed signifi-
cant changes, and contrary to what was expected, no increase
in the level of expression was detected [11,32]. We observed
minor variations in c-fos expression levels, which could not be
attributed to the suppression of DREAM mRNA since the rel-
ative expression of c-fos in other non-DREAM siRNA-trans-
fected SFLCs showed similar fluctuations. Thus, the in vitro
Figure 1
Qualitative results of reverse transcription-polymerase chain reactions  (PCRs) using DREAM primer and DREAM nested primer Qualitative results of reverse transcription-polymerase chain reactions 
(PCRs) using DREAM primer and DREAM nested primer. (a) DREAM 
amplicons of 409 base pairs (bp) in size in total RNA derived from cer-
ebellum and spinal cord, which served as positive controls. (b) Ampli-
cons of the expected size after reamplification from total RNA isolated 
from normal synovial fibroblast-like cells (NSFLCs) and osteoarthritis 
synovial fibroblast-like cells (OA-SFLCSs). (c) DREAM amplicon of 
409 bp and the amplicon resulting from nested PCR, starting from the 
PCR mix, which did not show any product on the agarose gel. The size 
of the smaller amplicon corresponds to the expected size of 276 bp. 
(d) Sequence of the amplicon. Positions of primers are highlighted in 
bold (DREAM forward and reverse) and bold italics (nested DREAM 
forward and reverse). DREAM, downstream regulatory element antago-
nist modulator.
Figure 2
Relative DREAM gene expression in peripheral blood mononuclear  cells from osteoarthritis (OA) patients and healthy controls Relative DREAM gene expression in peripheral blood mononuclear 
cells from osteoarthritis (OA) patients and healthy controls. Relative 
gene expression was normalized to GAPDH (glyceraldehyde-3-phos-
phate dehydrogenase) and is given as delta CT (dCT) value, with 
higher values representing lower expression levels. DREAM gene 
expression was significantly lower in OA patients with a high pain score 
(visual analog scale [VAS] score of greater than 40; ) compared with 
healthy controls (❍) and with OA patients with a low pain score (VAS 
score of less than or equal to 40; ∇). No significant differences were 
observed between healthy controls and OA patients with a VAS score 
of less than or equal to 40. Statistics: one-way analysis of variance fol-
lowed by Tukey's honest significant difference (*P < 0.05). Ctrl, con-
trol; DREAM, downstream regulatory element antagonist modulator.Arthritis Research & Therapy    Vol 10 No 3    Reisch et al.
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knockout of DREAM might not be sufficient to ensure the tran-
scription of pdyn in SFLCs compared with other models [33].
Additional factors might be necessary to initiate the transcrip-
tion of both reporter genes in the analyzed cell type. Moreover,
no protein was detectable with the antibodies used in this
study (Figure 4). The concentration of DREAM might have
been the limiting factor. The presence of DREAM in neuronal
tissue could be shown in all experiments. Due to the very low
endogenous level of protein, other publications dealing with
DREAM in vitro experiments report the use of stably trans-
fected cell lines to analyze the function and interactions of
DREAM [18,19,34-37].
It has been demonstrated that immune cell-derived opioids
play an important role in peripheral analgesia (reviewed in
[38,39]). Leukocytes containing β-endorphin, methionine-
enkephalin, and dynorphin-A migrate to the site of injury and/
or inflammation where the opioid peptides are released and
help to inhibit pain [40-42]. Therefore, we expected to find ele-
vated pdyn mRNA levels in PBMCs derived from patients suf-
fering from pain. But no pdyn mRNA was detected. In addition,
contradicting the theory of DREAM action on pain relief, a
reduction of the expression level of DREAM was shown in
PBMCs from OA patients with a VAS score of greater than 40
(Figure 2). Less DREAM mRNA was detected in the group of
patients suffering from strong and persistent pain.
In vitro and in vivo experiments show a reduction of DREAM
mRNA; in both cases, no changes in levels of pdyn mRNA
were detected. It cannot be ruled out that these negative find-
ings were due to concentrations of transcript near the
detection limit of the methods used. Nonetheless, the tran-
scriptional inhibition of DREAM mRNA did not lead to a
changed expression of the chosen reporter genes in in vitro
experiments using siRNA. In addition, in the in vivo situation, a
reduction of DREAM expression coincides with enhanced
pain. Reduced DREAM mRNA expression appears not to be
sufficient to relieve pain and/or counteract other mechanisms
induced by chronic pain, which possibly include dramatic
changes in the transcriptome in conditions of chronic pain.
The reduction of DREAM and the sustained release of dynor-
phin could also be a part of an increase in pain perception,
similar to the observation that opiate administration paradoxi-
cally can induce hyperalgesia [43,44].
Figure 3
Specific downregulation of DREAM mRNA expression Specific downregulation of DREAM mRNA expression. (a) The effect 
of five different small interfering RNAs (siRNAs) tested. All show an 
overall reduction in DREAM expression of 70% to 90% compared with 
the expression in mock-transfected cells and cells transfected with 
siRNA-green fluorescence protein (100%). (b) Time course of reduced 
levels of DREAM expression in synovial fibroblast-like cells transfected 
with siRNA3 and siRNA4 and incubated 24, 48, and 72 hours. 
DREAM, downstream regulatory element antagonist modulator.
Figure 4
Immunoprecipitation of DREAM protein from different tissues (arrows) Immunoprecipitation of DREAM protein from different tissues (arrows). 
The DREAM antibody recognizes the glutathione S-transferase-tagged 
recombinant protein (10 ng; predicted size of 54 kDa) and the native 
protein from neuronal tissue (human occipital cortex). The immunopre-
cipitations show the two antibody bands detected by the secondary 
goat anti-mouse antibody (heavy and light chains), and in the last lane, 
resembling the immunoprecipitation from neuronal tissue, a DREAM-
specific signal of the expected size (~30 kDa) was detectable. 
DREAM, downstream regulatory element antagonist modulator; IP, 
immunoprecipitation; PBMC, peripheral blood mononuclear cell; SFLC, 
synovial fibroblast-like cell.Available online http://arthritis-research.com/content/10/3/R60
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Conclusion
The aim to knock out DREAM as a transcriptional repressor in
SFLCs in chronic pain, a major feature of OA, to induce the
transcription of pdyn and the subsequent release of dynorphin
could not be demonstrated. In addition to no significant
changes in the expression level of the target gene pdyn in
SFLCs, the presence of the pdyn  transcript could not be
detected in PBMCs. Therefore, the applied approach to
increase endogenous dynorphin in the periphery appears not
to be feasible, although increased expression of pdyn  has
been demonstrated in the spinal cord of dream-/- mice [11].
However, it has to be taken into account that an ambivalent
role of dynorphin has been described in the central nervous
system, where higher amounts of dynorphin lead to enhanced
pain [44-46]. It is nevertheless of importance that the gene
product itself does not appear to play a role in the inherent
KOR system previously described in SFLCs [47]. Therefore,
DREAM is not a target to locally reduce the intensity of chronic
pain in patients with arthritis.
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